Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

New Deal Between Emisphere Technologies Inc. (EMIS) and Novo Nordisk A/S (ADR) (NVO)

Page 1 of 2

On October 15, Emisphere Technologies Inc. (OTCMKTS:EMIS) announced an agreement with Novo Nordisk A/S (ADR) (NYSE:NVO) to develop and market oral formulations of four classes of the Danish company’s investigational molecules targeting metabolic disorders such as diabetes and obesity by utilizing Emisphere’s oral Eligen Technology. Let’s not forget to mention that Mark Rachesky’s MHR Fund Management LLC owns 81.18 million shares of Emisphere Technologies, which account for a whopping 65.8% of the company’s common stock.

Gilead GILD pharmacist store examing pharmaceutical stocks medical

kurhan /

But first, you should get familiar with what Insider Monkey can offer, besides the high-quality evidence-based articles. At Insider Monkey, we track hedge funds’ moves in order to identify actionable patterns and profit from them. Our research has shown that hedge funds’ large-cap stock picks historically underperformed the S&P 500 Total Return Index by an average of seven basis points per month between 1999 and 2012. On the other hand, the 15 most popular small-cap stocks among hedge funds outperformed the benchmark by an average of 95 basis points per month (read more details here). Since the official launch of our small-cap strategy in August 2012, it has performed just as predicted, returning over 102% and beating the market by more than 53 percentage points. We believe the data is clear: investors will be better off by focusing on small-cap stocks utilizing hedge fund expertise (while avoiding their high fees at the same time) rather than large-cap stocks.

The aforementioned deal stipulates that Emisphere licensed to Novo Nordisk the exclusive right to develop product candidates in three of the four molecule classes and the non-exclusive right in the remaining one using its technology. Under the terms of the agreement, Emisphere is set to receive $5.0 million as an upfront licensing fee, but can also collect up to $62.5 million in development and sales milestone payments for each of the exclusively-licensed molecule classes and up to $20 million for the remaining molecule class. In addition, Emisphere will receive royalties on potential sales of the “soon-to-be” commercialized products. Ultimately, the two parties also amended their existing license agreement for Novo Nordisk’s GLP-1 analogue semaglutide. As a result, Emisphere Technologies Inc. (OTCMKTS:EMIS) will receive a payment of $9.0 million in exchange for a reduction in future royalty payments.

Follow Emisphere Technologies Inc (LON:EMIS)
Trade (LON:EMIS) Now!

Let’s turn the page, where you can take a look at the hedge fund sentiment on Novo Nordisk and at other developments at the company.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!